Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations is a phase 3, interventional study registered as NCT06674343 by Peking Union Medical College Hospital, with a registry enrolment figure of 144 participants, started 2024-07-15 and due to reach its primary completion in 2026-12-31. Interventions recorded: Furmonertinib. Conditions listed: Advanced or Metastatic Non-small Cell Lung Cancer. Primary outcome: Progression Freae Survival (PFS). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed locally advanced or metastatic lung adenocarcinoma not amenable to curative surgery or radiotherapy;". Sites: China. No results are recorded here; the registry entry is the source.